Our findings were recently confirmed by Faillaci et al., who analyzed serum liver angiopoietin-2 and VEGF levels in 242 DAA-treated patients and found a DAA-mediated increase of VEGF and angiopoietin-2 supported the increased risk of HCC recurrence/occurrence during antiviral treatment [52]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.